Vanrafia, 2nd drug in Novartis' IgAN troika, crosses FDA finish line in payday for Chinook investors
When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...
In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...
In a statement, Nxera CEO Chris Cargill said Kaneko’s appointment will help the company “maximize our commercial activities ...
Senior FDA leaders are anticipating that the agency’s already lagging rate of routine food and drug inspections will ...
With concerns mounting and speculation swirling, the particulars of President Donald Trump’s much-touted “Liberation Day” ...
“These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression,” ...
The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...
Novo Nordisk is shaking up its executive team as it bids adieu to its longtime head of commercial strategy and corporate affairs. | Camilla Sylvest is stepping down from her role as executive vice ...
Havas Lynx New York also hired Megan Skelly as chief creative officer. Skelly’s 30-year career has included spells at agencies including Edelman, R/GA, 360i and Dentsu.
In the latest in a growing trend of pharma reshuffling moves in Asia, Marubeni Corporation is absorbing Sumitomo Pharma’s ...
Boehringer Ingelheim picked a challenging day to reveal its 2024 financial results and guidance for this year. | Boehringer ...
Out of the shadows, new CDMO Artis BioSolutions has decloaked on a mission to tackle the tricky production process for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback